Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Search or Filter
Results
showing 1-10 of 925
Impact of PEPFAR’s Stop Work Order on PrEP
The impact of the stop-work order on PrEP is expected to be severe. These slides reflect the results of an analysis drawing on key informant interviews with representatives of Ministries of Health and PrEP implementers between 27 January 2025, when...
Prevention Option:
PxWire Volume 15, Issue No. 1
In this special edition of Px Wire, AVAC is going beyond a quarterly update of biomedical HIV prevention. We look at how the new US Administration’s attack on global health can be expected to devastate HIV prevention, including the capacity to deliver existing PrEP options, the scale up of new PrEP products, and the paralyzing impact on research and development.
Prevention Option:
Global PrEP Uptake and PEPFAR’s Role, 2016-2024
AVAC’s Global PrEP Tracker has documented cumulative PrEP initiations on a quarterly basis for nearly a decade. This graph presents the final data collected while PEPFAR was fully operational—PEPFAR support was responsible for 79% of PrEP uptake globally in the last year and reached 83% by the end of September of 2024. Data on the fourth quarter of 2024 is inaccessible since PEPFAR was taken offline in late January.
Prevention Option:
HIV Incidence, Age 15-49
Looking backward and then into the future, this chart shows actual HIV rates alongside projected rates with and without current prevention strategies (PrEP, VMMC, and free condoms).
Prevention Option:
Where We Are Now with LEN for PrEP
The chaos in foreign assistance programs (including discontinuation of major PrEP programs), cuts in staffing and new demands on donor commitments will make decisions on the procurement of LEN for PrEP more complex and uncertain.
Prevention Option:
Trials & Projects Halted by USAID Funding Suspension
The stop-work orders have disrupted USAID-supported HIV prevention research, halting critical investigations in vaccine and next-generation PrEP strategies.
Prevention Option:
Global Health in the Lurch: What’s happening now and who is pushing back?
A snapshot of global Health in the first weeks of the Trump Administration, this episode covers the impact of the US freeze on foreign aid to critical federal agencies and the HIV research pipeline and explores action in Congress and among civil society to push back.
New Product Introduction Update
A graphic showing ongoing studies of injectable cabotegravir and the dapivirine vaginal ring in eastern and southern Africa.
FAPP Response to NIH Cuts to Indirect Research Costs
Federal AIDS Policy Partnership Research Working Group urges Congressional leaders to support the restraining order preventing the National Institutes of Health (NIH) from unlawfully stripping funds that sustain cutting-edge medical and public health research at universities and research institutions nationwide.
Cabotegravir Volume
Allocation of non-commercial cabotegravir for PrEP supply in low- and middle-income countries, 2023-2026, as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on...
Prevention Option:
